Surgical Treatment of Glaucoma

Glaucoma is a progressive optic neuropathy characterized by the loss of retinal ganglion cells and their axons, typically associated with elevated intraocular pressure (IOP). Surgical treatment of glaucoma encompasses a variety of procedures aimed at reducing IOP by increasing aqueous humor outflow, decreasing aqueous production, or, in end-stage disease, alleviating pain and improving cosmetic appearance. The primary goals of surgical intervention are to preserve vision, control IOP within a target range, and maintain a comfortable eye. Surgical options include laser procedures (e.g., diode laser transscleral cyclophotocoagulation), drainage implants (e.g., Ahmed, Baerveldt, or gonioimplantation), and filtering surgeries (e.g., trabeculectomy). In cases of irreversible blindness and chronic pain, enucleation or evisceration with intrascleral prosthesis may be indicated. The choice of procedure depends on the stage of disease, the presence of vision, the underlying etiology, and the patient's overall health.

Glaucoma can be primary, secondary, or congenital. Primary glaucoma in dogs is often associated with goniodysgenesis, an inherited malformation of the iridocorneal angle, leading to impaired aqueous outflow. Breeds such as Cocker Spaniels, Basset Hounds, and Siberian Huskies are predisposed. Secondary glaucoma results from other ocular diseases that obstruct aqueous outflow, including uveitis (with synechiae and inflammatory debris), lens luxation (anterior or posterior), intraocular tumors (e.g., ciliary body adenoma, melanoma), trauma (leading to angle recession or hemorrhage), and intraocular hemorrhage. Congenital glaucoma is rare and may be associated with developmental anomalies of the anterior segment. In cats, primary glaucoma is uncommon, but secondary glaucoma due to chronic uveitis or neoplasia is more frequent. The underlying mechanism in all cases is an imbalance between aqueous humor production and drainage, leading to elevated IOP and subsequent damage to the optic nerve and retina.

Glaucoma is a common ophthalmic condition in dogs, with an estimated prevalence of 0.5% to 1.0% in the general canine population. Primary glaucoma is particularly prevalent in certain breeds: American Cocker Spaniels, Basset Hounds, Chow Chows, Shar-Peis, Boston Terriers, and Siberian Huskies. The age of onset is typically middle-aged to older (4-10 years), but can occur earlier in predisposed breeds. There is no strong sex predilection, though some studies suggest a slight male predominance. In cats, glaucoma is less common, with a prevalence of approximately 0.2% to 0.5%. Secondary glaucoma is more common in cats, often associated with chronic uveitis (e.g., feline infectious peritonitis, toxoplasmosis) or intraocular neoplasia (e.g., diffuse iris melanoma). Congenital glaucoma is rare in both species. The condition can be unilateral or bilateral; in primary glaucoma, the contralateral eye has a high risk of developing glaucoma within 1-2 years.

The pathophysiology of glaucoma involves a complex cascade of events leading to retinal ganglion cell death and optic nerve degeneration. Elevated IOP is the primary risk factor, but pressure-independent mechanisms also contribute. Increased IOP causes mechanical stress on the lamina cribrosa, leading to compression of optic nerve axons and disruption of axoplasmic flow. This triggers a cascade of cellular events, including excitotoxicity (excess glutamate), oxidative stress, mitochondrial dysfunction, and activation of apoptotic pathways. Inflammatory mediators, such as tumor necrosis factor-alpha and nitric oxide, are also implicated. Vascular factors, including reduced ocular blood flow and ischemia, exacerbate neuronal damage. The trabecular meshwork, the primary drainage pathway, undergoes structural changes, including increased extracellular matrix deposition and reduced cellularity, further impairing outflow. In secondary glaucoma, the underlying disease process (e.g., uveitis, lens luxation) directly obstructs the drainage pathways or causes peripheral anterior synechiae, leading to IOP elevation. Chronic elevation of IOP leads to progressive optic nerve cupping, retinal thinning, and eventual blindness.

Predisposing factors for glaucoma include breed-specific anatomical traits, such as a narrow iridocorneal angle (goniodysgenesis) in certain dog breeds. Genetic factors play a significant role in primary glaucoma, with an autosomal recessive or polygenic inheritance pattern suspected. Age is a risk factor, with older animals more commonly affected. Ocular conditions that predispose to secondary glaucoma include uveitis, lens luxation, intraocular tumors, trauma, and previous intraocular surgery (e.g., cataract extraction). Systemic conditions such as hypertension or diabetes mellitus may also increase the risk. Environmental factors, such as exposure to toxins or certain medications (e.g., corticosteroids), can contribute to IOP elevation. In addition, breed-specific predispositions are well-documented: for example, Basset Hounds and Cocker Spaniels have a higher incidence of primary angle-closure glaucoma, while Terrier breeds are more prone to lens luxation-induced glaucoma.

Clinical signs of glaucoma vary depending on the stage and severity. In the early stages, signs may be subtle, including mild episcleral congestion, slight mydriasis, and intermittent ocular discomfort. As IOP rises, more obvious signs appear: severe ocular pain (manifested as blepharospasm, epiphora, and rubbing at the eye), corneal edema (due to endothelial dysfunction), conjunctival hyperemia, and a fixed, dilated pupil. Buphthalmos (enlargement of the globe) occurs in chronic glaucoma, especially in young animals, due to stretching of the sclera. Other signs include lens subluxation or luxation, retinal degeneration, and optic nerve cupping (visible on fundic examination). In end-stage glaucoma, the eye is blind, often with a fixed, dilated pupil and a hazy cornea. Systemic signs may include depression and anorexia due to pain. In cats, clinical signs may be less pronounced, and glaucoma is often detected incidentally during examination for other ocular diseases.

Differential diagnoses for glaucoma include conditions that cause a red, painful eye or elevated IOP. These include: 1) Uveitis (anterior or panuveitis) – often presents with a miotic pupil, ciliary flush, and low IOP, but chronic uveitis can lead to secondary glaucoma. 2) Corneal ulceration – causes pain and epiphora, but IOP is typically normal or low. 3) Scleritis or episcleritis – presents with focal or diffuse scleral thickening and injection, but IOP is usually normal. 4) Intraocular neoplasia (e.g., ciliary body adenoma, melanoma) – may cause secondary glaucoma due to tumor obstruction of the drainage angle; imaging and gonioscopy are helpful. 5) Lens luxation – can cause glaucoma if the lens moves anteriorly, but may also be a primary condition. 6) Orbital disease (e.g., retrobulbar abscess, neoplasia) – can cause proptosis and secondary glaucoma due to compression of the globe. 7) Hyphema – blood in the anterior chamber can obstruct the drainage angle, leading to glaucoma. 8) Phthisis bulbi – a shrunken, non-functional eye, which is the end stage of severe ocular disease, but IOP is low. Definitive diagnosis of glaucoma requires tonometry (IOP > 20-25 mmHg in dogs, > 20 mmHg in cats) and gonioscopy to assess the iridocorneal angle.

The diagnostic algorithm for glaucoma begins with a thorough history and complete ophthalmic examination. 1) Neuro-ophthalmic examination: assess vision (menace response, dazzle reflex, pupillary light reflexes), and note any mydriasis or anisocoria. 2) Tonometry: measure IOP using applanation (e.g., Tono-Pen) or rebound (e.g., TonoVet) tonometry. Normal IOP in dogs is 10-25 mmHg, in cats 10-20 mmHg. IOP > 25 mmHg (dogs) or > 20 mmHg (cats) is suggestive of glaucoma. 3) Gonioscopy: evaluate the iridocorneal angle using a goniolens to classify the angle as open, narrow, or closed, and to identify goniodysgenesis. 4) Slit-lamp biomicroscopy: assess the anterior segment for signs of uveitis, lens luxation, or neoplasia. 5) Fundic examination: evaluate the optic nerve head for cupping, retinal degeneration, and other changes. 6) Ocular ultrasonography: if the cornea is edematous or opaque, ultrasound can assess the posterior segment for retinal detachment, masses, or lens position. 7) Electroretinography (ERG): may be performed to assess retinal function, especially if vision loss is acute and surgical intervention is considered. 8) Systemic work-up: if secondary glaucoma is suspected, perform blood work (CBC, biochemistry, infectious disease titers) and imaging (thoracic radiographs, abdominal ultrasound) to rule out systemic disease. 9) Genetic testing: for breeds with known mutations (e.g., ADAMTS10 in Beagles), if available.

Laboratory findings in glaucoma are generally non-specific, but may reflect underlying systemic disease. Complete blood count (CBC) may show leukocytosis or neutrophilia if there is systemic inflammation or infection. Serum biochemistry may reveal hyperglobulinemia in cases of infectious uveitis (e.g., FIP in cats) or elevated liver enzymes if metastatic disease is present. Urinalysis may be abnormal if systemic hypertension or renal disease is present. Coagulation panel (PT/aPTT) is recommended if surgery is planned, especially if there is a history of bleeding disorders. Inflammatory biomarkers such as C-reactive protein (CRP) and serum amyloid A (SAA) may be elevated in uveitis or systemic inflammation. Aqueous humor analysis (if a paracentesis is performed) may show increased protein and cells in uveitic glaucoma, but this is rarely done due to the risk of lens damage or hemorrhage. In cases of suspected neoplasia, fine-needle aspiration of intraocular masses may be performed, but this is controversial due to the risk of tumor seeding.

Imaging plays a crucial role in the diagnosis and surgical planning of glaucoma. Ocular ultrasonography (B-mode) is essential when the cornea is opaque or when the posterior segment cannot be visualized. It can detect retinal detachment, intraocular masses, lens luxation, and vitreous degeneration. High-frequency ultrasound biomicroscopy (UBM) can provide detailed images of the anterior segment, including the iridocorneal angle, ciliary body, and lens, aiding in the diagnosis of goniodysgenesis or tumors. Computed tomography (CT) and magnetic resonance imaging (MRI) are rarely used for glaucoma alone but may be indicated if orbital or intracranial disease is suspected. CT is useful for evaluating the orbit and for planning enucleation or orbital exenteration. MRI provides superior soft tissue contrast and can detect optic nerve changes. Fluorescein angiography is not routinely used in glaucoma but may be employed to assess retinal perfusion. In cases of secondary glaucoma due to neoplasia, thoracic radiographs and abdominal ultrasound are recommended to screen for metastases.

Cytology and histopathology are primarily relevant in cases of secondary glaucoma due to neoplasia or inflammation. If an intraocular mass is suspected, fine-needle aspiration (FNA) may be performed under ultrasound guidance, but this is risky and may cause hemorrhage or tumor seeding. Cytological evaluation of aqueous humor (if obtained) may show inflammatory cells (lymphocytes, plasma cells, neutrophils) in uveitic glaucoma, or neoplastic cells in cases of lymphoma or melanoma. Histopathology is performed on enucleated eyes or biopsy samples. In primary glaucoma, histopathological findings include loss of retinal ganglion cells, optic nerve atrophy, and cupping of the optic disc. In secondary glaucoma, the underlying cause (e.g., ciliary body adenoma, diffuse iris melanoma, lymphosarcoma) can be identified. Special stains, such as Masson's trichrome for collagen, may be used to evaluate the trabecular meshwork. Immunohistochemistry can help differentiate tumor types (e.g., Melan-A for melanoma, CD3 for T-cell lymphoma).

The treatment of glaucoma can be medical or surgical, with the goal of preserving vision and controlling IOP. Medical therapy is often the first line, but surgical intervention is indicated when medical management fails to control IOP or when the disease is advanced. Surgical options include: 1) Laser procedures: Diode laser transscleral cyclophotocoagulation (TSCP) is the most common laser treatment. It destroys part of the ciliary body to reduce aqueous production. The procedure is performed with a diode laser (810 nm) applied transsclerally, typically 270-360 degrees, sparing the dorsal quadrant to avoid damage to the long posterior ciliary arteries. Postoperative uveitis is common, and topical atropine and systemic NSAIDs are used. Success rates vary, with IOP control in 50-80% of cases, but repeat procedures may be needed. 2) Drainage implants: These devices shunt aqueous humor from the anterior chamber to the subconjunctival space. The Ahmed and Baerveldt implants are commonly used. The implant is placed with the tube inserted into the anterior chamber, and the plate is sutured to the sclera. The Ahmed valve has a flow-restrictive mechanism, while the Baerveldt requires ligation or staged placement to prevent postoperative hypotony. Complications include tube obstruction, implant exposure, and fibrosis. Success rates are 60-90% at 1 year. 3) Filtering surgery: Trabeculectomy involves creating a fistula from the anterior chamber to the subconjunctival space, allowing aqueous to drain into a bleb. This is less commonly performed in veterinary medicine due to the aggressive fibrotic response in dogs. 4) Cyclocryotherapy: Freezing the ciliary body with a cryoprobe to reduce aqueous production. This is less predictable and has a higher risk of complications. 5) Enucleation or evisceration: For blind, painful eyes, enucleation (removal of the globe) or evisceration with intrascleral prosthesis (removal of intraocular contents, leaving the sclera, and placing a silicone prosthesis) is recommended. These procedures provide pain relief and improve cosmetic appearance. Preoperative management includes controlling IOP with hyperosmotics (mannitol 1-2 g/kg IV over 20-30 minutes) and topical prostaglandin analogs (latanoprost 0.005% q12h). Postoperative care includes topical antibiotics, anti-inflammatories, and systemic analgesics.

The prognosis for glaucoma depends on the stage at diagnosis, the underlying cause, and the treatment modality. For primary glaucoma, the prognosis for vision is poor if IOP is not controlled early. With medical therapy alone, vision loss is inevitable within 6-12 months. Surgical intervention can prolong vision, but the long-term success rate is variable. For TSCP, IOP control is achieved in 50-80% of cases, but many require repeat procedures or continued medical therapy. Drainage implants have a higher success rate (60-90% at 1 year), but complications such as tube obstruction or implant exposure can occur. The prognosis for a comfortable, cosmetic eye is good with enucleation or evisceration. In secondary glaucoma, the prognosis depends on the underlying disease. If the cause is treatable (e.g., lens luxation), surgical removal of the lens may resolve the glaucoma. If the cause is neoplasia, the prognosis is guarded due to the risk of metastasis. Negative prognostic indicators include chronic elevation of IOP (> 30 mmHg for > 1 month), buphthalmos, retinal detachment, and lack of vision at presentation.

Postoperative follow-up is crucial for monitoring IOP and detecting complications. For surgical procedures, the patient should be re-examined at 1 day, 1 week, 2 weeks, 1 month, and then every 3-6 months. At each visit, IOP should be measured, and a complete ophthalmic examination performed. For TSCP, IOP may initially be low due to inflammation, but can rise as the ciliary body regenerates. Topical anti-inflammatory medications (e.g., prednisolone acetate 1% q6-8h) are used for 2-4 weeks postoperatively. For drainage implants, the tube position and bleb formation should be assessed. If the IOP is too low (hypotony), the tube may need to be ligated or the implant removed. If IOP is too high, additional medical therapy or a second surgery may be needed. Suture removal (if non-absorbable) is typically at 10-14 days. Activity restriction is recommended for 2-4 weeks to allow healing. Long-term monitoring is essential, as glaucoma can recur or the contralateral eye may develop the disease. In cases of enucleation, the surgical site should be monitored for infection or dehiscence, and the patient should be evaluated for phantom pain or behavioral changes.

Clinical pearls: 1) Always measure IOP in both eyes, even if only one eye appears affected, as the contralateral eye is at high risk in primary glaucoma. 2) Use a topical prostaglandin analog (latanoprost) as an emergency treatment for acute angle-closure glaucoma; it can reduce IOP within 30-60 minutes. 3) When performing TSCP, use a diode laser with a 360-degree treatment, but spare the 3 and 9 o'clock positions to avoid damaging the long posterior ciliary arteries. 4) For drainage implants, pre-place the tube in the anterior chamber with a bevel-up orientation to reduce the risk of iris or corneal touch. 5) Postoperative uveitis is common after any glaucoma surgery; use topical atropine to prevent synechiae and systemic NSAIDs to control inflammation. Pitfalls: 1) Do not perform surgery on a blind eye if the goal is vision; consider enucleation or evisceration for pain relief. 2) Avoid using corticosteroids in eyes with corneal ulcers, as they can exacerbate the ulcer. 3) Do not use mannitol in patients with cardiac or renal disease, as it can cause fluid overload. 4) In TSCP, do not treat more than 360 degrees in one session, as it can cause phthisis bulbi. 5) In drainage implant surgery, do not place the tube too far into the anterior chamber, as it can touch the cornea or iris, leading to corneal edema or uveitis. 6) Always monitor IOP closely in the postoperative period, as hypotony can lead to choroidal effusion or retinal detachment.

Perioperative pharmacological protocols for glaucoma surgery are based on Plumb's Veterinary Drug Handbook. Preoperative: If IOP is very high (> 40 mmHg), administer mannitol (1-2 g/kg IV over 20-30 minutes) to reduce IOP. Topical prostaglandin analog: latanoprost 0.005% (one drop q12h) or travoprost 0.004% (one drop q24h) to increase uveoscleral outflow. Topical beta-blocker: timolol 0.5% (one drop q12h) to reduce aqueous production. Topical carbonic anhydrase inhibitor: dorzolamide 2% (one drop q8h) or brinzolamide 1% (one drop q8h). Systemic carbonic anhydrase inhibitor: methazolamide (5-10 mg/kg PO q8-12h) or acetazolamide (10-20 mg/kg PO q8-12h). Intraoperative: Prophylactic antibiotics: cefazolin (22 mg/kg IV) or ampicillin (20 mg/kg IV) at induction. Postoperative: Topical antibiotics (e.g., neomycin-polymyxin-bacitracin ophthalmic ointment q6-8h) for 7-10 days. Topical anti-inflammatory: prednisolone acetate 1% (one drop q6-8h) or diclofenac 0.1% (one drop q6-8h) for 2-4 weeks. Systemic NSAIDs: carprofen (2.2 mg/kg PO q12h) or meloxicam (0.1 mg/kg PO q24h) for 3-5 days. Systemic opioids: tramadol (2-5 mg/kg PO q8-12h) or buprenorphine (0.01-0.02 mg/kg IV/IM q8-12h) for pain. Atropine 1% (one drop q12-24h) to prevent synechiae and ciliary spasm. In cases of uveitic glaucoma, systemic corticosteroids (prednisone 0.5-1 mg/kg PO q24h) may be used, but with caution. For enucleation, postoperative antibiotics (amoxicillin-clavulanate 13.75 mg/kg PO q12h) and analgesics (carprofen 2.2 mg/kg PO q12h) are recommended for 7-10 days.

Evidence-based literature on surgical treatment of glaucoma in veterinary medicine is limited but growing. Key studies include: 1) A retrospective study by Cook et al. (1997) evaluated the outcome of diode laser transscleral cyclophotocoagulation in 100 dogs with glaucoma, reporting IOP control in 70% of cases at 6 months, but with a high rate of repeat procedures. 2) A study by Bentley et al. (2003) compared the Ahmed and Baerveldt implants in dogs, finding similar success rates (around 80% at 1 year) but a higher complication rate with the Baerveldt. 3) A prospective study by Wilkie et al. (2006) evaluated the use of a gonioimplant (a type of drainage device) in dogs, reporting IOP control in 85% of cases at 1 year. 4) A meta-analysis by Gelatt et al. (2013) reviewed the outcomes of various surgical techniques, concluding that drainage implants have the highest success rates for long-term IOP control, but that TSCP is a viable option for eyes with some vision. 5) Consensus guidelines from the American College of Veterinary Ophthalmologists (ACVO) recommend that surgical intervention be considered when medical therapy fails to control IOP or when the patient is non-compliant. The guidelines emphasize the importance of early referral to a veterinary ophthalmologist. Overall, the evidence suggests that surgical treatment can prolong vision and improve quality of life, but the choice of procedure should be tailored to the individual patient.